Expression Analysis of Circulating miR-21, miR-34a and miR-122 and Redox Status Markers in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients with and Without Type 2 Diabetes
Authors:
Open Access
- 7 March 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2392
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), a hepatic form of metabolic syndrome, often co-occurs with type 2 diabetes (T2D) and now affects approximately 30% of the global population. MASLD encompasses conditions from simple steatosis to metabolic dysfunction-associated steatohepatitis, with oxidative stress (OS) driving progression through inflammation. This study analyzes the expression levels of circulating miRNAs and redox status markers in MASLD patients with and without T2D, exploring their potential as disease biomarkers. The expressions of miR-21, miR-34a, and miR-122 were analyzed in the platelet-poor plasma of 147 participants, divided into three groups: MASLD + T2D (48), MASLD (50), and a control group (49). Total oxidant status (TOS), total antioxidant status (TAS), ischemia-modified albumin (IMA), and superoxide anion radical (O2•−) were measured in serum and plasma. Logistic regression showed that miR-21, miR-34a, TOS, TAS, O2•−, and IMA were positive predictors of MASLD, while miR-21 and TAS were negative predictors of T2D in MASLD. Although miR-122 did not show a significant association with either condition, in combination with miR-34a and other markers such as lipid status and liver enzymes, a new significant predictor of MASLD was identified. Circulating miRNAs in combination with redox status markers, lipid status and liver enzymes show potential as MASLD biomarkers.Keywords
Funding Information
- Ministry of Science, Technological Development and Innovation, Republic of Serbia (451-03-65/2024-03/200161)
This publication has 62 references indexed in Scilit:
- Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessmentJournal of Physiology and Biochemistry, 2024
- Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causalityDiabetologia, 2019
- Long-term inhibition of miR-21 leads to reduction of obesity in db/db miceObesity, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liverClinica Chimica Acta, 2013
- MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signalingBiomedicine & Pharmacotherapy, 2013
- The role of oxidative stress in non-alcoholic steatohepatitisClinica Chimica Acta, 2011
- Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular CarcinomaCancer Cell, 2011
- Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits HypothesisHepatology, 2010
- Origins and Mechanisms of miRNAs and siRNAsCell, 2009